R&D Pipeline
Currently, our disclosed development pipeline is following.
Development Pipeline
＜Pharmaceuticals＞
| Development code, substance name | Indication | Developed in | Stage | Remarks |
|---|---|---|---|---|
| SI-6603 Condoliase |
Lumbar disc herniation | USA | Phase III | Exclusive Worldwide License Agreement (excluding Japan) for SI-6603 with Ferring Pharmaceuticals (Switzerland) |
| SI-613 Hyaluronic Acid-Diclofenac Conjugates |
Osteoarthritis | Japan | Phase III | Definitive agreement related to co-development and marketing collaboration on SI-613 with Ono Pharmaceutical |
| Knee osteoarthritis | USA | Phase II | ||
| SI-613-ETP Hyaluronic Acid-Diclofenac Conjugates |
Enthesopathy | Japan | Late-stage Phase II | Definitive agreement related to co-development and marketing collaboration on SI-613 with Ono Pharmaceutical |
| SI-614 Modified Hyaluronate |
Dry eye | USA | Phase II/III |
＜Medical Devices＞
| Development code, substance name |
Description | Developed in | Stage | Remarks |
|---|---|---|---|---|
| SI-449 Cross-linked Chondroitin Sulfate |
Adhesion barrier | Japan | Pilot study |
(As of May 21, 2018)
Outline of development theme
SI-6603 (treatment for lumbar disc herniation - developed in the U.S.)
SI-6603 is a treatment option for lumbar disc herniation with the active pharmaceutical ingredient of condoliase. This is therapeutic agent with intradiscal administration. It does not require a general anesthesia and is less invasive to the patient than surgical treatment. As this agent specifically degrades GAGs in the nucleus pulposus, resulting in decrease in the pressure on the nerve root by a single administration of the agent, Seikagaku believes that this new treatment option is able to contribute to quality of life of the patient.
The Japanese Ministry of Health, Labour and Welfare (MHLW) approved the New Drug Application (NDA) of HERNICORE 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation, on March 23, 2018. HERNICORE was launched on August 1, 2018.
SI-613 (treatment of osteoarthritis - developed in Japan and the U.S.)
SI-613-ETP (treatment of enthesopathy - developed in Japan)
SI-613 is a formulation in which hyaluronic acid and a diclofenac (anti-inflammatory drug)
are chemically bound using Seikagaku’s own proprietary technology. SI-613 was designed to provide pain relief and anti-inflammatory effect by sustained release of diclofenac, and the joint function improving effect by hyaluronic acid. It is expected to provide prompt and sustained relief of the severe pain and inflammation associated with osteoarthritis and enthesopathy. Since SI-613 is administered directly into the joint cavity or near the tendon or ligament enthesis as an injectable treatment, the transfer of the NSAID into the systemic blood is extremely low, and it is expected to mitigate the risk of side effects reported in oral or transdermal administration of NSAID.
SI-614 (treatment of dry eye - developed in the U.S.)
SI-614 is a modified hyaluronate that is produced using the Company’s proprietary technology. Ocular instillation of SI-614 in patients with dry eye is expected to protect the ocular surface and promote corneal wound healing.
SI-449 (adhesion barrier - developed in Japan)
SI-449 is a powdered adhesion barrier whose main ingredient is cross-linked chondroitin sulfate developed using Seikagaku’s own glycosaminoglycan cross-linking technology. SI-449, which has the property of absorbing moisture and swelling, is expected to prevent or mitigate post-operative adhesion formation by forming a barrier between the surgical wound site and surrounding tissues after application.
Seikagaku is considering introducing SI-449 not only in Japan, but in global.
